Projet ALKATRAS (Horizon 2020, appel à projets 2015)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

This ETN is embedded into an established international research programme; The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA; www.erialcl.net) is an existing and functional network of 13 partners, which will cosset and nurture a cohort of early stage researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives. ERIA was instigated to coordinate research into ALK-related malignancies to facilitate the development of less-toxic and more efficacious therapies. ALK is increasingly recognised as a prevalent oncogene in a number of human malignancies and therefore poses a prominent clinical problem, which requires coordinated research into its oncogenic mechanisms. ERIA now conducts a collaborative multidisciplinary research programme at the interface of biomedical and bio-mechanistic approaches, which will be an excellent environment to train the next generation of European scientists. The 15 recruited fellows will be incorporated into international academic study groups (all partners of the ERIA network) to perform high calibre research and also will be exposed to environments from other sectors to broaden their experience. Secondments will include technical training within individual laboratories and SMEs (TissueGnostics, Galkem, Cambridge Life Sciences, Sofigen and Varionostics) as well as large Pharma (Roche). Training through research will be complemented with a balanced programme of transferable skills and access to local courses. The training of each fellow will be guided by a personal career development plan and supervised by a PhD committee panel. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into an international network. Thereby providing competence in state-of-the-art research and development at the forefront of translational science.

Mots clés : lymphoma, anaplastic lymphoma kinase

Participants :
- Medical University of Graz (Autriche) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Roche (Austria) (Autriche) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Tissuegnostics gmbh (Autriche) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Varionostic gmbh (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 525751.2 €
- Medical University of Vienna (Autriche) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 574216.55 €
- Charité - Universitätsmedizin Berlin (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University of Turin (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 258061.32 €
- Biolution (Austria) (Autriche) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Masaryk University (Rép. Tchèque) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 232422.48 €
- University of Cambridge (Royaume-Uni) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 546575.76 €
- Galkem srl (Italie) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Naked science ltd (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Giessen (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University of Milano-Bicocca (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 258061.32 €
- University of Gothenburg (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 263659.32 €
- Sofigen (Rép. Tchèque) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Freiburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University of Tübingen (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- Central European Society for Anticancer Drug Research (Autriche) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ludwig Boltzmann Gesellschaft (Autriche) — Partner, beneficiary, Recherche, subvention : 193585.69 €
- Institut Gustave Roussy (France) — Partner, beneficiary, Recherche, subvention : 0.0 €
- Cambridge Life Sciences (United Kingdom) (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €